JP2023550444A5 - - Google Patents

Info

Publication number
JP2023550444A5
JP2023550444A5 JP2023530323A JP2023530323A JP2023550444A5 JP 2023550444 A5 JP2023550444 A5 JP 2023550444A5 JP 2023530323 A JP2023530323 A JP 2023530323A JP 2023530323 A JP2023530323 A JP 2023530323A JP 2023550444 A5 JP2023550444 A5 JP 2023550444A5
Authority
JP
Japan
Prior art keywords
group
groups
membered
general formula
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023530323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550444A (ja
JP7849587B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/131642 external-priority patent/WO2022105852A1/zh
Publication of JP2023550444A publication Critical patent/JP2023550444A/ja
Publication of JP2023550444A5 publication Critical patent/JP2023550444A5/ja
Priority to JP2026021203A priority Critical patent/JP2026097848A/ja
Application granted granted Critical
Publication of JP7849587B2 publication Critical patent/JP7849587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023530323A 2020-11-20 2021-11-19 トリアジンジオン系誘導体、その調製方法及びその医薬的応用 Active JP7849587B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026021203A JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202011310827 2020-11-20
CN202011310827.4 2020-11-20
CN202110021509.4 2021-01-08
CN202110021509 2021-01-08
CN202110244090 2021-03-05
CN202110244090.9 2021-03-05
CN202110464375 2021-04-28
CN202110464375.3 2021-04-28
PCT/CN2021/131642 WO2022105852A1 (zh) 2020-11-20 2021-11-19 三嗪二酮类衍生物、其制备方法及其在医药上的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026021203A Division JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Publications (3)

Publication Number Publication Date
JP2023550444A JP2023550444A (ja) 2023-12-01
JP2023550444A5 true JP2023550444A5 (cg-RX-API-DMAC7.html) 2024-05-23
JP7849587B2 JP7849587B2 (ja) 2026-04-22

Family

ID=81708401

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023530323A Active JP7849587B2 (ja) 2020-11-20 2021-11-19 トリアジンジオン系誘導体、その調製方法及びその医薬的応用
JP2026021203A Pending JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026021203A Pending JP2026097848A (ja) 2020-11-20 2026-02-12 トリアジンジオン系誘導体、その調製方法及びその医薬的応用

Country Status (10)

Country Link
US (1) US20240010639A1 (cg-RX-API-DMAC7.html)
EP (1) EP4249474A4 (cg-RX-API-DMAC7.html)
JP (2) JP7849587B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230110538A (cg-RX-API-DMAC7.html)
CN (4) CN119638681A (cg-RX-API-DMAC7.html)
AU (1) AU2021381664B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198934A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005533A (cg-RX-API-DMAC7.html)
TW (1) TW202227420A (cg-RX-API-DMAC7.html)
WO (1) WO2022105852A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) * 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
CN117088854A (zh) * 2022-05-20 2023-11-21 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的可药用盐、晶型及制备方法
WO2023222103A1 (zh) 2022-05-20 2023-11-23 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的晶型及制备方法
WO2024056096A1 (zh) * 2022-09-16 2024-03-21 江苏豪森药业集团有限公司 一种含氮杂环酮化合物的晶型及其制备方法
WO2026130464A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 制备治疗肥厚型心肌病药物的用途
WO2026153470A1 (zh) * 2025-01-16 2026-07-23 江苏恒瑞医药股份有限公司 制备治疗非梗阻性肥厚型心肌病药物的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5502089B2 (ja) * 2008-10-09 2014-05-28 エフ.ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
SG173647A1 (en) * 2009-02-13 2011-10-28 Shionogi & Co Novel triazine derivative and pharmaceutical composition containing same
US20110319400A1 (en) * 2010-06-28 2011-12-29 Flores Christopher M Prokineticin 1 receptor antagonists for the treatment of pain
US9718790B2 (en) * 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
IL322175A (en) 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
CN111094300B (zh) * 2018-01-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
MA53491A (fr) * 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途

Similar Documents

Publication Publication Date Title
JP2024514837A5 (cg-RX-API-DMAC7.html)
JP2007507542A5 (cg-RX-API-DMAC7.html)
JP2021524838A5 (cg-RX-API-DMAC7.html)
JP2021529185A5 (cg-RX-API-DMAC7.html)
CN114401964A (zh) 一类具有brd4抑制活性的化合物、其制备方法及用途
CA2721098A1 (en) Oxo-heterocyclic substituted carboxylic acid derivates and the use thereof
JP2014503574A5 (cg-RX-API-DMAC7.html)
JP2009509971A5 (cg-RX-API-DMAC7.html)
JP2021529746A5 (cg-RX-API-DMAC7.html)
JP2007512283A5 (cg-RX-API-DMAC7.html)
JP2021535164A5 (cg-RX-API-DMAC7.html)
JP2012236838A5 (cg-RX-API-DMAC7.html)
JP2024508526A5 (cg-RX-API-DMAC7.html)
RU2005137403A (ru) Новые замещенные 3-сера-индолы
CA2694270A1 (en) Substituted aryloxazoles and the use thereof
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2020502047A5 (cg-RX-API-DMAC7.html)
JP2018529690A5 (cg-RX-API-DMAC7.html)
IL287159B1 (en) Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2017519796A5 (cg-RX-API-DMAC7.html)
RU2016137502A (ru) Изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
JP2020517619A5 (cg-RX-API-DMAC7.html)
JP2022534902A5 (cg-RX-API-DMAC7.html)
CA2666975C (en) Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same